Sagimet Biosciences Inc. Series A Common Stock (SGMT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sagimet Biosciences Inc. Series A Common Stock (SGMT) has a cash flow conversion efficiency ratio of -0.084x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.61 Million) by net assets ($102.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SGMT cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Sagimet Biosciences Inc. Series A Common Stock - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Sagimet Biosciences Inc. Series A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sagimet Biosciences Inc. Series A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sagimet Biosciences Inc. Series A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Sunyes Electronic Manufacturing Holding Co Ltd
SHE:002388
|
-0.066x |
|
Aurora Corp
TW:2373
|
-0.013x |
|
Orion Engineered Carbons SA
NYSE:OEC
|
-0.045x |
|
AbClon Inc
KQ:174900
|
-0.075x |
|
Costamare Bulkers Holdings Limited
NYSE:CMDB
|
0.034x |
|
Anhui Sunhere Pharmaceutical Excipients Co Ltd
SHE:300452
|
0.025x |
|
Key Ware Electronics Co Ltd
TWO:5498
|
0.032x |
|
Wuhan Nusun Landscape Co Ltd
SHE:300536
|
0.000x |
Annual Cash Flow Conversion Efficiency for Sagimet Biosciences Inc. Series A Common Stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Sagimet Biosciences Inc. Series A Common Stock from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see SGMT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $111.38 Million | $-45.65 Million | -0.410x | -50.48% |
| 2024-12-31 | $155.81 Million | $-42.44 Million | -0.272x | -4.36% |
| 2023-12-31 | $91.06 Million | $-23.77 Million | -0.261x | -299.22% |
| 2022-12-31 | $-186.95 Million | $-24.49 Million | 0.131x | -4.51% |
| 2021-12-31 | $-158.26 Million | $-21.71 Million | 0.137x | +79.00% |
| 2020-12-31 | $-135.91 Million | $-10.42 Million | 0.077x | -8.98% |
| 2019-12-31 | $-125.31 Million | $-10.55 Million | 0.084x | -- |
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfun… Read more